SCHEMBL23293136

SCHEMBL23293136

COc1cc(F)ccc1C(O)c1ccc(F)cc1OC

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.39
MGAM O43451 1/20 0.39
GAA P10253 1/20 0.39
SI P14410 1/20 0.39
MGAM2 Q2M2H8 1/20 0.39
ACHE P22303 1/20 0.39
NFE2L2 Q16236 1/20 0.38
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
HTT P42858 1/20 0.37
KMT2A Q03164 1/20 0.37
FFAR1 O14842 1/20 0.37
FFAR4 Q5NUL3 1/20 0.37
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM5 P08912 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36
F2RL1 P55085 5/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29922538 0.89 NFE2L2 (0.38) KDM4EMGAMGAASIMGAM2
SCHEMBL21830940 0.89 NFE2L2 (0.38) KDM4EMGAMGAASIMGAM2
SCHEMBL12993119 0.86 MGAM (0.42) KDM4EMGAMGAASIMGAM2
SCHEMBL12563119 0.86 MGAM (0.42) KDM4EMGAMGAASIMGAM2
SCHEMBL21352139 0.84 MAPT (0.40) ACHEMEN1MAPTHTTKMT2A
SCHEMBL30616709 0.84 ACHE (0.44) ACHEMAPTF2RL1
SCHEMBL23293462 0.84 ACHE (0.44) ACHEMAPTF2RL1
SCHEMBL14833888 0.83 APLNR (0.39) GAAACHEMEN1MAPTKMT2A
SCHEMBL31280542 0.83 PDE2A (0.45) KDM4EMGAMGAASIMGAM2
SCHEMBL19757661 0.83 PDE2A (0.45) KDM4EMGAMGAASIMGAM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112585139-B Naphthyridinone compounds as T cell activators 百时美施贵宝公司 2023-12-01 CN disclosed
EP-3814347-B1 NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2023-05-03 EP disclosed
EP-3814347-B1 NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2023-05-03 EP disclosed
US-20210277004-A1 NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2021-09-09 US disclosed
EP-3814347-A1 NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS Bristol-Myers Squibb Company (US) 2021-05-05 EP disclosed
CN-112585139-A Nalidinone compounds as T cell activators 百时美施贵宝公司 2021-03-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210277004-A1 NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKZ, DGKA, DGKG KDM4E 2027/4885MGAM 3910/4885GAA 1562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.